Investigative Treatment Shows Promise for Advanced Prostate Cancer

Video

New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

According to researcher Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, prostate cancer cells have the prostate-specific membrane antigen (PSMA) proteins on their surface. These proteins represent an excellent therapeutic target, Morris said, because they are not present on most normal tissues.

The investigative treatment 177Lu-PSMA-617 is being investigated in the VISION trial. It targets PSMA with high affinity and binds to the proteins’ external domain, Morris said. The drug emits beta-radiation, which allows the treatment to radiate the cell that it is attached to as well as several surrounding cells.

Related Videos
Image Credit: © Dragana Gordic - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
car t cell therapy multiple myeloma/Image Credit: © Lusi_mila - stock.adobe.com
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room - Image credit: pressmaster | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
cancer pain management | Image Credits: © Burlingham - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.